Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil, Bayer Aleve Ad Dispute Heats Up With Federal Lawsuit

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals' has taken its dispute with Bayer Consumer Care over advertising for Aleve to court, after a NAD decision apparently failed to resolve the conflict

You may also be interested in...



Aleve “Doctor Recommended” Ad Claim Has No “Reasonable Basis” – NAD

Bayer Consumer Care should modify TV ads comparing the company's Aleve analgesic with McNeil Consumer and Specialty Pharmaceuticals' Tylenol "to avoid conveying a 'doctor recommended message,'" the National Advertising Division of the Council of Better Business Bureaus says

Aleve “Doctor Recommended” Ad Claim Has No “Reasonable Basis” – NAD

Bayer Consumer Care should modify TV ads comparing the company's Aleve analgesic with McNeil Consumer and Specialty Pharmaceuticals' Tylenol "to avoid conveying a 'doctor recommended message,'" the National Advertising Division of the Council of Better Business Bureaus says

Aleve “Doctor Recommended” Ad Claim Has No “Reasonable Basis” – NAD

Bayer Consumer Care should modify TV ads comparing the company's Aleve analgesic with McNeil Consumer and Specialty Pharmaceuticals' Tylenol "to avoid conveying a 'doctor recommended message,'" the National Advertising Division of the Council of Better Business Bureaus says

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel